Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsNewsAboutContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

News

Remdesivir

(Veklury®)

Veklury®

Drug updated on 4/22/2024

Dosage FormInjection (intravenous: 100 mg/20 mL)
Drug ClassSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleotide analogs
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older and weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, who are hospitalized, or not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Remdesivir (Veklury) is indicated for the treatment of COVID-19 in adults and pediatric patients who are hospitalized or not, with mild-to-moderate disease severity, and at high risk for progression to severe COVID-19.
  • A total of 36 systematic reviews/meta-analyses were reviewed to gather information about this drug's safety and effectiveness.
  • In terms of safety, Remdesivir (Veklury) has been associated with potentially fewer serious adverse events compared to placebo as well as other treatments such as Convalescent Plasma according to one study.
  • Compared against Hydroxychloroquine (HCQ), which displayed a concerning safety profile causing longer time to clinical recovery and higher all-cause mortality alongside more total adverse events, Remdesivir (Veklury) appears safer based on the studys reviewed.
  • The effectiveness of Remdesivir(Veklury) was highlighted through positive outcomes regarding reduction in mortality rates and improvements in clinical recovery times when compared with placebo or standard care.
  • While Dexamethasone showed significant benefits particularly among those requiring respiratory support suggesting its effectiveness in severe cases that Veklury also aims address but within a general patient group; comparative efficacy between these drugs remains complex due low certainty evidence available for Veklury(Remdisvir).
  • Subgroup considerations revealed that the benefit from using remdesivir(Velkurry) was specifically notable among hospitalized patients but not universally across all degrees of disease severity; however lack significant subgroup analyses limits understanding its effectivity across different populations like age groups or comorbid conditions etc.
  • Remdisvir's potential use along side dexamethasone & possibly baricitinib could represent multilayered approach addressing viral replication inflammatory response respectively especially hospitalised Covid 19 patients without requirement high flow oxygen.

Product Monograph / Prescribing Information

Document TitleYearSource
Veklury (remdesivir) Prescribing Information.2024Gilead Sciences Inc., Foster City, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Remdesivir for the treatment of COVID-19. 2023Cochrane Database of Systematic Reviews
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials.2023The Lancet
Acute kidney injury in COVID-19 patients receiving remdesivir: a systematic review and meta-analysis of randomized clinical trials.2023Clinics
Cost-effectiveness of remdesivir for the treatment of hospitalized patients with COVID-19: a systematic review.2023Infectious Diseases of Poverty
Remdesivir for pregnancy: a systematic review of antiviral therapy for COVID-19. 2022Heliyon
Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials. 2022BMJ Open
Potentially effective drugs for the treatment of COVID‑19 or MIS‑C in children: a systematic review. 2022European Journal of Pediatrics
Diagnostics and treatments of COVID-19: a living systematic review of economic evaluations. 2022Value in Health
Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials. 2022BMC Infectious Diseases
Comparative efficacy and safety of pharmacological interventions for severe COVID-19 patients: an updated network meta-analysis of 48 randomized controlled trials.2022Medicine
Efficacy of pharmacological interventions in COVID-19: a network meta-analysis.2022British Journal of Clinical Pharmacology
The clinical efficacy and safety of anti-viral agents for non-hospitalized patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials. 2022Viruses
Remdesivir for the treatment of patients hospitalized with COVID‑19 receiving supplemental oxygen: a targeted literature review and meta‑analysis.2022Scientific Reports
Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials.2022BMJ Open
Efficacy of COVID-19 treatments among geriatric patients: a systematic review.2022Therapeutic Advances in Infectious Disease
Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis. 2021European Journal of Pharmacology
Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis of randomized controlled trials.2021Contemporary Clinical Trials
Remdesivir for adults with COVID-19: a living systematic review for American College of Physicians Practice Points. 2021Annals of Internal Medicine
Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis. 2021BMJ Open
Major update: remdesivir for adults with COVID-19: a living systematic review for American College of Physicians Practice Points. 2021Annals of Internal Medicine
Effectiveness of remdesivir, lopinavir/ritonavir, and favipiravir for COVID-19 treatment: a systematic review. 2021International Journal of General Medicine
Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials. 2021Journal of Antimicrobial Chemotherapy
Remdesivir for the treatment of coronavirus COVID-19: a meta-analysis of randomised controlled trials. 2021Journal of Global Antimicrobial Resistance
Remdesivir for coronavirus disease 2019 (COVID-19): a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. 2021Infectious Diseases
Major update 2: remdesivir for adults with COVID-19: a living systematic review for American College of Physicians Practice Points. 2021Annals of Internal Medicine
Efficacy of COVID-19 treatments: a Bayesian network meta-analysis of randomized controlled trials. 2021Frontiers in Public Health
Current evidence for COVID-19 therapies: a systematic literature review.2021European Respiratory Review
Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider. 2021Annals of the Rheumatic Diseases
Interventions for treatment of COVID-19: second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). 2021PLoS One
Comparative effectiveness of pharmacological interventions for Covid-19: a systematic review and network meta-analysis. 2021Frontiers in Pharmacology
Antiviral drugs for coronavirus disease 2019 (COVID-19): a systematic review with network meta-analysis. 2021Expert Review of Anti-infective Therapy
Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. 2020PLoS Medicine
Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis. 2020Life Sciences
Immune therapy, or antiviral therapy, or both for COVID‑19: a systematic review. 2020Drugs
SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence. 2020American Journal of Emergency Medicine
Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis.2020BMJ Supportive & Palliative Care
Interventions for treatment of COVID-19: a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). 2020PLOS Medicine
Drug treatments for covid-19: living systematic review and network meta-analysis. 2020BMJ
Efficacy of various treatment modalities for nCOV-2019: a systematic review and meta-analysis.2020European Society for Clinical Investigation
Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis. 2020PLoS One

Clinical Practice Guidelines

Document TitleYearSource
Coronavirus disease 2019 (COVID-19) treatment guidelines. 2022National Institutes of Health
Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19. 2022Infectious Diseases Society of America
COVID-19 rapid guideline: managing COVID-19.2021NICE
Remdesivir for severe COVID-19: a clinical practice guideline. 2020The BMJ
A living WHO guideline on drugs for covid-19.2020The BMJ